Compare Stocks: SABS, MGTX, ORIC, and IMTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMTX Immatics	$8.79 +0.5%	$9.34	$5.67 ▼ $12.41	$1.20B	1.33	651,536 shs	527,248 shs
MGTX MeiraGTx	$12.79 -0.5%	$13.20	$6.62 ▼ $15.35	$1.23B	1.27	724,249 shs	459,547 shs
ORIC Oric Pharmaceuticals	$12.04 -0.2%	$12.36	$7.23 ▼ $14.93	$1.25B	1	1.03 million shs	1.06 million shs
SABS SAB Biotherapeutics	$3.41 -0.3%	$3.70	$1.85 ▼ $5.15	$310.26M	0.53	271,639 shs	712,046 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMTX Immatics	+0.46%	-8.05%	-9.47%	-6.29%	+51.29%
MGTX MeiraGTx	-0.47%	-7.92%	-1.31%	+33.37%	+70.76%
ORIC Oric Pharmaceuticals	-0.25%	-6.38%	-12.44%	+45.59%	+14.45%
SABS SAB Biotherapeutics	-0.29%	-8.33%	-10.26%	+2.40%	+60.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMTX Immatics	$8.79 +0.5%	$9.34	$5.67 ▼ $12.41	$1.20B	1.33	651,536 shs	527,248 shs
MGTX MeiraGTx	$12.79 -0.5%	$13.20	$6.62 ▼ $15.35	$1.23B	1.27	724,249 shs	459,547 shs
ORIC Oric Pharmaceuticals	$12.04 -0.2%	$12.36	$7.23 ▼ $14.93	$1.25B	1	1.03 million shs	1.06 million shs
SABS SAB Biotherapeutics	$3.41 -0.3%	$3.70	$1.85 ▼ $5.15	$310.26M	0.53	271,639 shs	712,046 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMTX Immatics	+0.46%	-8.05%	-9.47%	-6.29%	+51.29%
MGTX MeiraGTx	-0.47%	-7.92%	-1.31%	+33.37%	+70.76%
ORIC Oric Pharmaceuticals	-0.25%	-6.38%	-12.44%	+45.59%	+14.45%
SABS SAB Biotherapeutics	-0.29%	-8.33%	-10.26%	+2.40%	+60.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMTX Immatics	2.63	Moderate Buy	$20.60	134.36% Upside
MGTX MeiraGTx	3.00	Buy	$26.17	104.59% Upside
ORIC Oric Pharmaceuticals	2.79	Moderate Buy	$19.60	62.79% Upside
SABS SAB Biotherapeutics	2.73	Moderate Buy	$12.00	251.91% Upside

Current Analyst Ratings Breakdown

Latest SABS, MGTX, ORIC, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/25/2026	IMTX Immatics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$17.00
8/20/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	MGTX MeiraGTx	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$26.00 ➝ $27.00
8/13/2026	MGTX MeiraGTx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/10/2026	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$25.00 ➝ $27.00
8/6/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (E+)
7/17/2026	MGTX MeiraGTx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ORIC Oric Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
7/8/2026	MGTX MeiraGTx	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$25.00 ➝ $26.00

(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMTX Immatics	$41.70M	28.81	N/A	N/A	$4.09 per share	2.15
MGTX MeiraGTx	$81.39M	15.09	N/A	N/A	($0.07) per share	-182.71
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.90 per share	N/A
SABS SAB Biotherapeutics	N/A	N/A	$0.34 per share	10.01	$3.18 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMTX Immatics	-$222.26M	-$1.86	N/A	N/A	N/A	-495.71%	-47.41%	-39.45%	11/17/2026 (Estimated)
MGTX MeiraGTx	-$114.20M	$0.71	18.01	N/A	N/A	19.87%	283.85%	29.39%	11/12/2026 (Estimated)
ORIC Oric Pharmaceuticals	-$129.47M	-$1.35	N/A	N/A	N/A	N/A	-35.35%	-33.39%	11/12/2026 (Estimated)
SABS SAB Biotherapeutics	$13.27M	-$1.30	N/A	N/A	N/A	N/A	-6.74%	-6.06%	11/13/2026 (Estimated)

Latest SABS, MGTX, ORIC, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	IMTX Immatics	-$0.4748	-$0.53	-$0.0552	-$0.52	$12.42 million	$10.44 million
8/13/2026	Q2 2026	MGTX MeiraGTx	-$0.4583	$1.71	+$2.1683	$1.71	$0.70 million	$321.43 million
8/6/2026	Q2 2026	SABS SAB Biotherapeutics	-$0.2830	-$0.28	+$0.0030	-$0.28	$0.13 million	N/A
8/3/2026	Q2 2026	ORIC Oric Pharmaceuticals	-$0.3594	-$0.38	-$0.0207	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMTX Immatics	N/A	7.54	7.54
MGTX MeiraGTx	0.46	3.76	3.76
ORIC Oric Pharmaceuticals	N/A	13.19	13.19
SABS SAB Biotherapeutics	0.01	9.22	9.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMTX Immatics	64.41%
MGTX MeiraGTx	67.48%
ORIC Oric Pharmaceuticals	95.05%
SABS SAB Biotherapeutics	7.82%

Insider Ownership

Company	Insider Ownership
IMTX Immatics	3.30%
MGTX MeiraGTx	7.40%
ORIC Oric Pharmaceuticals	5.70%
SABS SAB Biotherapeutics	7.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMTX Immatics	260	136.69 million	132.18 million	Optionable
MGTX MeiraGTx	300	96.04 million	88.94 million	Optionable
ORIC Oric Pharmaceuticals	80	103.65 million	97.75 million	Optionable
SABS SAB Biotherapeutics	140	90.99 million	84.26 million	Not Optionable

SABS, MGTX, ORIC, and IMTX Headlines

Recent News About These Companies

SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10 at 3:00 PM | seekingalpha.com

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Analysts

September 5, 2026 | americanbankingnews.com

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of "Moderate Buy" by Brokerages

September 5, 2026 | marketbeat.com

SAB BIO to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

375,000 Shares in SAB Biotherapeutics, Inc. $SABS Purchased by AWM Investment Company Inc.

August 26, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and SAB Biotherapeutics (SABS)

August 8, 2026 | theglobeandmail.com

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

August 6, 2026 | globenewswire.com

SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment

July 15, 2026 | finance.yahoo.com

SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial

July 12, 2026 | theglobeandmail.com

SAB Biotherapeutics, Inc.: Breakthrough T1D Awards Grant to Support PRISE-hATG Study of SAB-142 in Stage 3 Type 1 Diabetes

July 7, 2026 | finanznachrichten.de

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

July 7, 2026 | globenewswire.com

Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?

July 6, 2026 | finance.yahoo.com

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

May 29, 2026 | finance.yahoo.com

SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

May 29, 2026 | globenewswire.com

Citigroup initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation

May 23, 2026 | msn.com

Why SAB Biotherapeutics, Inc.’s (SABS) Stock Is Up 7.01%

May 21, 2026 | aaii.comA

SAB Biotherapeutics Inc SABS

May 20, 2026 | morningstar.comM

Jefferies initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation

May 20, 2026 | msn.com

SAB Biotherapeutics Signs Manufacturing Pact for SAB-142

May 16, 2026 | theglobeandmail.com

We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully

May 16, 2026 | finance.yahoo.com

SAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...

May 12, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS, MGTX, ORIC, and IMTX Company Descriptions

Immatics NASDAQ:IMTX

$8.79 +0.04 (+0.46%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$8.80 +0.01 (+0.11%)

As of 09/11/2026 07:30 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

MeiraGTx NASDAQ:MGTX

$12.79 -0.06 (-0.47%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$13.03 +0.24 (+1.85%)

As of 09/11/2026 07:30 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Oric Pharmaceuticals NASDAQ:ORIC

$12.04 -0.03 (-0.25%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$12.04 +0.01 (+0.04%)

As of 09/11/2026 07:30 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

SAB Biotherapeutics NASDAQ:SABS

$3.41 -0.01 (-0.29%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.53 +0.12 (+3.52%)

As of 09/11/2026 07:30 PM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SABS, MGTX, ORIC, and IMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SABS, MGTX, ORIC, and IMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SABS, MGTX, ORIC, and IMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS, MGTX, ORIC, and IMTX Company Descriptions

Immatics NASDAQ:IMTX

MeiraGTx NASDAQ:MGTX

Oric Pharmaceuticals NASDAQ:ORIC

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SABS, MGTX, ORIC, and IMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SABS, MGTX, ORIC, and IMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SABS, MGTX, ORIC, and IMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS, MGTX, ORIC, and IMTX Company Descriptions

Immatics NASDAQ:IMTX

MeiraGTx NASDAQ:MGTX

Oric Pharmaceuticals NASDAQ:ORIC

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools